Gliosis

The supplied grounding supports gliosis as a response to central nervous system insults and degenerative lesions rather than a primary disease with a single cause. It is described in association with ischemic stroke, traumatic brain injury, neuronal loss, pathological protein aggregation, and brain inflammation. The grounding also links astrogliosis to pain models induced by HIV-1 gp120 and chronic morphine administration.

Gliosis reflects reactive astrocyte activation, with morphological, proliferative, and functional changes collectively termed astrogliosis. These changes are associated with increased monoamine oxidase B levels in astrocytes and can be visualized as a marker of ongoing astrocytic proliferation. The literature describes both pathogenic and protective effects, including possible limitation of injury spread and contributions to altered neural circuit plasticity.

The grounding supports CNS injury and degenerative pathology as contexts associated with gliosis. Examples include ischemic stroke, traumatic brain injury, neuronal loss, pathological protein aggregation, and brain inflammation. It is also associated with pain-pathway models involving HIV-1 gp120 and chronic morphine exposure.

No disease-specific standard treatment for gliosis is supported in the supplied grounding. The literature instead discusses management at the level of underlying CNS injury or disease and experimental modulation of reactive astrocytes. Imaging with MAO-B PET is described as a way to visualize and quantify astrogliosis, not as treatment.